12 Apr

Xtandi: A Key Oncology Pillar in 2019

WRITTEN BY Margaret Patrick

Xtandi’s growth trends

According to Pfizer’s (PFE) fourth-quarter earnings conference call, Xtandi is a pillar of the company’s oncology business. In 2018, Pfizer managed to earn $1.0 billion combined from alliance revenues on the sale of Xtandi in the US market and royalty income on the drug’s ex-US sales.

To learn more about Xtandi’s revenue performances in the fourth quarter and 2018, read Pfizer: Ibrance and Xtandi Are Key Oncology Assets.

Xtandi: A Key Oncology Pillar in 2019

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Growth strategy

Pfizer has been focused on increasing the uptake of Xtandi by urologists, mainly in mCRPC (metastatic castration-resistant prostate cancer) indications. At the end of 2018, almost 30% of the drug’s new prescriptions were written by urologists.

On July 13, Pfizer and Astellas Pharma issued a press release announcing the FDA’s approval of Xtandi in non-mCRPC indications based on the Phase 3 PROSPER trial’s results. According to Pfizer’s fourth-quarter earnings conference call, at the end of 2018, Xtandi’s market share in non-mCRPC indications was four times greater than that of its competitor Johnson & Johnson’s (JNJ) Erleada and similar to the combined market share of Erleada and chemotherapy.

According to Pfizer’s fourth-quarter earnings conference call, the company is focusing on the growth opportunity for Xtandi in hormone-positive prostate cancer indications, and it expects to see benefits related to longer therapy durations in this patient population.

On February 11, Pfizer and Astellas Pharma issued a press release announcing positive results from the Phase 3 ARCHES trial evaluating a combination regimen of Xtandi and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer indications. Pfizer expects to expand Xtandi’s label in this indication and target 38,000 new patients annually.

According to Pfizer’s fourth-quarter earnings conference call, Pfizer and Astellas Pharma are expecting data readouts from the Phase 3 EMBARK trial evaluating Xtandi in non-metastatic hormone-positive prostate cancer indications in 2020. If it’s approved by the FDA, the drug is expected to target 30,000 new patients annually in this indication.

According to Pfizer’s fourth-quarter earnings conference call, it expects its launch of the generic version of competitor drug Zytiga to have a minimal impact on Xtandi’s adoption due to differences in the drugs’ approved indications and their dosing frequencies.

Latest articles

23 May

Trade War Subdues Manufacturing PMIs around the World

WRITTEN BY Mayur Sontakke, CFA, FRM

Today, IHS Markit published its purchasing managers' indexes or PMIs for May countries around the world.

Best Buy (BBY) reported better-than-expected earnings for the first quarter of fiscal 2020, which ended on May 4.

23 May

Why Apple Stock Is Down 2.7% Today

WRITTEN BY John Parker

On May 23 at 12:46 PM EDT, Apple (AAPL) was trading at $179.12 with a 2.0% loss for the day.

The CBOE Volatility Index has been sitting at very low levels for most of 2019.

23 May

Cannabis Stocks Fell Due to Trade Fears

WRITTEN BY Adam Jones

On May 23, CannTrust (CTST) was trading nearly 4.1% lower, while Cronos Group (CRON) fell 3.3%.

US equity markets are in the red today amid the escalation in the US-China trade war.

172.31.16.229